| Test | Code | Sample Reqs | Turnaround | Special Instructions
|
| 1p36 Deletion Syndrome MLPA only |
MRML |
A |
10 days |
9 |
| 21-Hydroxylase Deficiency (Congenital Adrenal Hyperplasia) 7 mutations + deletions/duplications |
GENE |
2xA |
8 weeks |
9,11 |
| 22q11 deletion (DiGeorge Syndrome) karyotype + FISH |
KARY, FISH |
H |
12-17 days |
9 |
| 22q11 deletions (DiGeorge Syndrome) MLPA only |
MRML |
A |
10 days |
9 |
| 5Fluorouracil Toxicity (DPD deficiency) common mutation (IVS14+1G>A) |
5FU |
A |
5 days |
9 |
| 5Fluorouracil Toxicity (DPD deficiency) rare mutations |
GENE |
2xA |
3 weeks |
9,11 |
| Achondroplasia 2 common mutations in FGFR3 (c.1138G>A + c.1138G>C) |
ACHP |
A |
5 days |
9 |
| Acoustic Neuroma (NF2) sequencing + deletions/duplications |
GENE |
2xA |
8 weeks |
9,11 |
| Alpers Syndrome 3 common POLG mutations (p.A467T + p.W748S + p.G848S) |
GENE |
A |
4 weeks |
9,11 |
| Alpha 1 Antitrypsin genotype PI*M, PI*S, PI*Z |
ATPH |
A |
5 days |
9 |
| Alpha Fetoprotein on Amniotic fluid |
AFPA |
AF |
5-10 days |
9 |
| Alpha Thalassaemia multiplex PCR for common large deletions |
GENE |
2xA |
3 weeks |
9,11 |
| Alpha Thalassaemia alpha-globin sequencing |
GENE |
2xA |
6 weeks |
9,11 |
| Amnio PCR only trisomy analysis by QF-PCR |
APC |
AF |
1-2 days |
9 |
| Amniocentesis culture (karyotype) |
ACUL |
AF |
10-15 days |
9 |
| Androgen Insensitivity AR sequencing + deletions/duplications |
GENE |
2xA |
8 weeks |
9,11 |
| Angelman Syndrome (Primary Screen) methylation PCR |
PWAM |
A |
5 days |
9 |
| Angelman Syndrome UBE3A hotspot sequencing |
GENE |
2xA |
8 weeks |
9,11 |
| Angelman Syndrome karyotype + FISH |
KARY, FISH |
H |
12-17 days |
9 |
| Angelman Syndrome UPD 15 (parents and child) |
UPD |
A/AF |
10 days |
9,12 |
| Aniridia Tier 1 PAX6 sequencing |
GENE |
2xA |
10 weeks |
9,11 |
| Aniridia Tier 2 PAX6 deletions |
|
|
4 weeks |
|
| Apo E genotyping by PCR E2, E3, E4 |
APEG |
A |
5 days |
9 |
| Array CGH (Comparative Genomic Hybridisation) |
GENE |
2xA |
3 months |
9,11 |
| Ashkenazi Jewish Array 77 mutations, 22 genes |
GENE |
2xA |
12 weeks |
9,11 |
| Ashkenazi Breast Cancer Screen 3 common mutations |
GENE |
A |
4 weeks |
9,11 |
| Ashkenazi Jewish Carrier Screen |
ASHJ |
A |
5 days |
9 |
| Azoospermia Y deletion + karyotype + cystic fibrosis screen + polyT |
CAVD |
2xA, H |
10-15 days |
9 |
| Bannayan-Riley-Ruvalcaba Syndrome (BRRS) PTEN sequencing + deletions/duplications |
GENE |
2xA |
4 weeks |
9,11 |
| BCR/ABL (Chronic Myeloid Leukemia) fusion gene PCR + Philidelphia chromosome (9:22 translocation) analysis |
BABL |
Contact Lab |
10 days |
|
| Becker Muscular Dystrophy deletions/duplications |
DND |
A |
10 days |
9,11 |
| Beckwith-Wiedemann Syndrome methylation studies on 11p15 imprinting domains KvDMR + H19 |
GENE |
2xA |
4 weeks |
9,11 |
| Beta Thalassaemia beta-globin sequencing |
BGS |
2xA |
6 weeks |
9,11 |
| Bloom Syndrome common c.2207-12 deletion |
BLOM |
A |
5 days |
9 |
| Breast Cancer BRCA1 and BRCA2 full sequencing + deletions/duplications |
BRCA |
2xA |
6 weeks |
9,11 |
| Breast Cancer Ashkenazi Screen 3 common mutations |
Contact consultant clinical geneticist |
|
| GENE |
A |
4 weeks |
9,11 |